Alligator Bioscience Reports P-II Study (OPTIMIZE-1) Interim Results of Mitazalimab as 1L Treatment of Pancreatic Cancer
Shots:
- The ongoing P-II study (OPTIMIZE-1) evaluating mitazalimab in combination with CT (mFOLFIRINOX) in patients with mPDAC. The results are expected in Q1’24
- The results showed an ORR of 52% in pre-planned interim efficacy analysis among 23 evaluable patients as per the response evaluation criteria in solid tumors (RECIST 1.1), DCR, ORR, or stabilization of disease was ≥90%
- Mitazalimab was safe and tolerable at 900µg/kg in combination with mFOLFIRINOX, as previously reported in the P-Ib dose escalation phase of the trial. The company intends to talk with regulators in the EU & EU about these positive results to explore a potential accelerated development and approval pathway for mitazalimab
Ref: Alligator Bioscience | Image: Alligator Bioscience
Related News: Orion Signs a License and Research Agreement with Alligator to Develop Bispecific Antibody for the Treatment of Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
